| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP, Head Of R&D | Chief Medical Officer
1 company
Randhawa Simrat is an EVP, Head Of R&D at Dianthus Therapeutics, Inc.. Recent SEC Form 4 filings include 2 buys and 8 sells.
Estimated insider holdings value: $1.2M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | DNTH Dianthus Therapeutics, Inc. | EVP, Head Of R&D | Sale+OE | 26,530 | $90.62 | $2,404,076.95 | -41.6% | - | - | |
| Mar 12, 2026 | DNTH Dianthus Therapeutics, Inc. | EVP, Head Of R&D | Sale+OE | 33,830 | $81.48 | $2,756,468.40 | -100% | -4.9% | - | |
| Nov 14, 2025 | DNTH Dianthus Therapeutics, Inc. /de/ | EVP, Head Of R&D | Sale+OE | 196,538 | $37.55 | $7,379,887.46 | -67.2% | +16.2% | - | |
| Sep 22, 2023 | DNTH Dianthus Therapeutics, Inc. /de/ | Chief Medical Officer | Buy | 4,000 | $13.20 | $52,800.00 | +200.0% | -34.7% | +109.0% |